You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 10,722,473


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,722,473
Title:Methods and compositions particularly for treatment of attention deficit disorder
Abstract: There is described, inter alia, a coated bead comprising: (a) a granule; (b) a first layer coated over the granule, the first layer comprising a first amount of an active pharmaceutical ingredient comprising a central nervous system stimulant; and (c) a second layer coated over the first layer, the second layer being present in an amount sufficient to substantially delay release of the active pharmaceutical ingredient in the first layer until after the coated bead reaches a distal intestine portion of a subject to whom the coated bead is administered; and (d) the third layer coated over the second layer, the third layer comprising a second amount of the active pharmaceutical ingredient, the third layer being configured to permit substantially immediate release of the active pharmaceutical ingredient comprised therein. Embodiments related to a solid oral pharmaceutical composition are also described.
Inventor(s): Donnelly; Graeme (Toronto, CA), Bhaskar; Sailaja (Pickering, CA)
Assignee: Purdue Pharma L.P. (Stamford, CT)
Application Number:16/195,418
Patent Claims: 1. A method of treating Attention Deficit Hyperactivity Disorder (ADHD) in a pediatric subject from 6 to 11 years of age, the method comprising administering to the pediatric subject from 6 to 11 years of age in need thereof, an oral pharmaceutical composition comprising from 25 to 100 mg methylphenidate hydrochloride, wherein the oral solid pharmaceutical composition, when administered to a pediatric subject from 6 to 11 years of age in a fasted state, provides an average methylphenidate AUC.sub.0-4 (pghr/mL) that is from 80 to 125% of the value resulting from the formula: Average AUC.sub.0-4=804.42*(dose of methylphenidate hydrochloride in mg)-b 8994.4 further wherein the oral solid pharmaceutical composition provides efficacious treatment of ADHD for 16 hours after a single oral administration.

2. The method of claim 1, wherein the oral pharmaceutical composition further provides an average methylphenidate AUC.sub.8-14 (pghr/mL) that is from 80 to 125% of the value resulting from the formula: Average AUC.sub.8-14=1580.3*(dose of methylphenidate hydrochloride in mg)-1860.

3. The method of claim 1, wherein the oral pharmaceutical composition further provides an average methylphenidate AUC.sub.14-24 (pghr/mL) that is from 80 to 125% of the value resulting from the formula: Average AUC.sub.14-24=1392.2*(dose of methylphenidate hydrochloride in mg)-9239.1.

4. The method of claim 1, wherein the oral pharmaceutical composition further provides an average methylphenidate AUC.sub.0-.infin. (pghr/mL) that is from 80 to 125% of the value resulting from the formula: Average AUC.sub.0-.infin.=5932*(dose of methylphenidate hydrochloride in mg)-51578.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.